Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)
The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing. Participants will: * Receive one of four possible combinations of medications * Undergo an MRI * Complete questionnaires * Undergo transcranial magnetic stimulation (TMS) and EEG
• Age 18 to 65 years at screening, of any identified gender and racial/ethnic group
• Physically healthy; does not meet criteria for an exclusionary medical condition
• English-speaking (able to provide consent and complete questionnaires)
• Modest decrement in self-reported wellbeing without the presence of a DSM-5 Axis I mood or anxiety disorder
• Able to undergo magnetic resonance imaging (MRI) and transcranial magnetic stimulation (TMS)